While global deep-tech ventures routinely grapple with delayed non-dilutive capital—such as US R&D tax credits or SBIR grants—Australian founders operate under specific Australian Taxation Office (ATO) R&D Tax Incentive rules where cash timing is make-or-break. For eligible companies with aggregated turnover under $20 million, the refundable offset sits at the company tax rate plus 18.5 percentage points. However, this cash becomes available only after annual returns are lodged and processed, not when vendors require payment for reagents.
Biotech financial models adapted from software templates routinely collapse because they ignore this capital lag, underprice single-month equipment deposits, and miscalculate specialized lab recruitment timelines. At jamessackl.com.au, James Sackl, founder of Wallace Biotechnologies, argues that founders should treat first-year financial estimates as inherently conservative: incorporate a baseline 40 percent cash contingency above initial pre-seed projections, ensuring the company can still reach assay validation with six months of reserve runway remaining.
Why Biotech Startup Funding Models Break Before the Seed Round
Model the Development Cycle in Milestones
Build the pre-seed model around technical milestones and monthly cash events. Each milestone carries its own staffing and laboratory costs, plus whatever equipment and external validation it needs, and each one gets modeled twice more: once for a schedule slip, once for a result that doesn’t work. A single smooth forecast hides the outcome that matters most: eight weeks of salaries spent on an experiment that produces no saleable asset.
Sackl’s position is that founders should price that outcome before an investor asks about it. Across his own ventures, he says first-year cash requirements have run roughly 40 percent above the original estimate, and he offers that as his own observation rather than a sector benchmark.
Show Cash Timing Rather Than Annual Totals
Annual totals hide the timing differences that decide whether you make payroll. A monthly view can’t. Separate accrued expenses from committed spending, and separate both from cash actually paid, because a $60,000 instrument deposit and a 12-month software license can hit the bank account in one month while the accounting treatment spreads them across several periods. Financing receipts belong in the month you reasonably expect them to land, with a note explaining what triggers each one.
Biotech Startup Burn Rate Benchmarks Need Context
Define the Numbers Investors Are Reading
Three numbers do most of the work in a seed conversation. Gross burn is total monthly cash outflow. Net burn subtracts cash receipts from that. Runway divides unrestricted cash by expected net burn, adjusted where future spending changes materially.
That last calculation gets shaky as soon as a hiring wave, custom antibody synthesis lead times, microfluidic chip fabrication delays, or major equipment payments hit the schedule. A company burning $45,000 a month with two laboratory hires starting in March isn’t a $45,000-a-month company; its projected burn may soon rise to $70,000. Show both historical trailing burn and projected forward burn. Founders must rely strictly on hard operational metrics over optimism—if the data indicates a hire or experiment is failing, adjust the plan immediately rather than assuming the figures are an anomaly.
“Believe the dial, not the feeling in your gut,” said Sackl. “I’ve sat looking at a number that meant a hire wasn’t working, or a product was done, with my whole gut insisting the number was a fluke. The gut was the fluke.”
How Much Runway Does a Biotech Startup Need?
Enough to reach the next value-changing milestone and get through the fundraising process that follows it, with room left over for a delay you defined in advance. Investors assess burn against the evidence a company can produce before it needs more capital, so no single monthly threshold fits every biotech business. An 18-to-24-month range works as a planning assumption. It isn’t a rule. A wet-laboratory venture shouldn’t assume a bridge round will close quickly, and regulated products usually need longer coverage than laboratory hardware businesses that can reach paid pilot work early.
Replace Fixed Thresholds With an Investor Test
Seed investors are unlikely to work from a single published cutoff. They typically want straight answers on four fronts and a use-of-funds bridge connecting this round to the next financing event. A deck that gets there early tends to shorten diligence.
| Metric | What the deck should show | Investor concern it addresses |
| Monthly gross burn | Current and post-hiring outflow | Cost visibility |
| Monthly net burn | Outflow after recurring receipts | Cash consumption |
| Milestone cash balance | Cash remaining when the evidence is delivered | Financing resilience |
| Delay case | Closing cash after a defined schedule slip | Planning discipline |
Forecasting the Australian R&D Tax Incentive for Biotech Startups
Model the expected offset in the period you reasonably expect to receive it, using the rules for the relevant income year, and carry a downside case for a payment that arrives late or comes in smaller than planned. To bridge the lag between spending and tax return processing, founders should evaluate specialized R&D advance financing facilities, which allow startups to borrow against their accrued tax offset at a cost far lower than equity dilution. Registration remains separate from tax-return lodgement; the Department of Industry, Science and Resources requires companies to register eligible activities within 10 months of the income year’s end.
Eligible expenditure is also narrower than the total research budget. The Income Tax Assessment Act 1997 generally requires at least $20,000 in notional deductions, subject to limited exceptions, before the offset applies. Keep uncertain items such as overseas contract work, capital purchases and general overhead outside the assumed eligible pool until a registered tax agent confirms their treatment.
Align Revenue Projections With Product Evidence
Use Stage-Gated Revenue
Revenue enters the forecast only after you can name the conditions it depends on, technical and regulatory as much as commercial. Signed revenue and probability-weighted pipeline belong on separate rows, and anything you can’t yet support goes on a third that’s labeled clearly enough that nobody mistakes it for a forecast. A market-size multiplier is not a revenue projection. Where a clinical pathway applies, the Therapeutic Goods Administration’s Australian Clinical Trial Handbook sets out the notification and approval routes that affect timing.
Distinguish Commercial Proof From Technical Progress
A working prototype is not recognized revenue. Between a validated device and a first invoice sit the procurement cycles inside hospitals and research institutes, and behind those, manufacturing readiness and the quality systems that hold it together.
Sackl frames the cost structure of diagnostics as a primary reason to model operational overhead precisely: “The reagents, the chemicals that do the actual reacting and give you the number, cost about 60 cents. The test sells for $39. So the thing you came for is under 2% of the bill. The other 98% is people and paperwork wrapped round 60 cents of chemistry.”
Automating that measurement layer brings unit costs down to cents, but driving down hardware expenses is only half the battle. Once those operational costs and assay outputs are accurately baseline-modeled, founders can build a predictive “digital twin”—a computational model that tracks biological variance and catches technical failures before they deplete physical runway.
“Get the cost right and the data shows up. Get the data and you build the twin, the model that catches a body drifting off balance and helps you set it right before it breaks.”
How to Avoid Early Cap Table Dilution
Finance the Evidence That Changes Valuation
A resource-intensive company can keep more equity by financing one evidence-producing milestone at a time and using nondilutive support where it fits. Grants and shared institutional infrastructure can push the equity round further out, and so can tightly scoped paid work. Delaying dilution at any cost has its own price, though. Grant reporting obligations and milestone covenants come with strings, and so do customer commitments that outlast the cash they arrived with.
Model Ownership Before Signing
Before executing priced equity rounds, pre-seed biotech startups often utilize non-priced bridge instruments like SAFEs (Simple Agreements for Future Equity) or convertible notes to defer valuation debates while securing capital for initial milestones. When transitioning to a formal priced round, run the capitalization arithmetic carefully. Note whether option pool expansions are required on a pre-money basis—which concentrates dilution onto existing founders—or a post-money basis. The scenario below is illustrative; consult a startup legal specialist before agreeing to term sheet allocations.
| Holder | Before round | After 20% new money | After 10% pool increase |
| Founders | 85% | 68% | 61.2% |
| Existing angels | 15% | 12% | 10.8% |
| New seed investors | 0% | 20% | 18% |
| Option pool | 0% | 0% | 10% |
Protect the Central Program
Contract work can fund runway and quietly divert the program at the same time, so it needs a written budget ceiling and a clear personnel boundary. One pattern that works: a senior scientist runs paid method-development work two days a week, covering annual access fees at a shared facility, while the validation team stays out of the client queue.
What Survives a Failed Run
Capital planning in a laboratory business holds up when the plan survives a failed run. Sackl puts it in investor terms: “Every dollar in the round should be attached to a piece of evidence that changes what the company is worth. If you cannot name the evidence, you are buying time, not progress.” Founders who keep more of their equity are usually the ones financing evidence rather than optimism. A model that still reaches its next milestone after a three-month slip changes the tone of the meeting: less defending assumptions, more negotiating terms.
